Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial.

[1]  M. Parmar,et al.  Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. , 2018, The Lancet. Oncology.

[2]  J. Griggs,et al.  Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Schorge,et al.  Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States. , 2016, Gynecologic oncology.

[4]  I. Vergote,et al.  Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. , 2016, Gynecologic oncology.

[5]  I. Vergote,et al.  Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Kasamatsu,et al.  Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. , 2016, European journal of cancer.

[7]  G. Scambia,et al.  Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. , 2016, European journal of cancer.

[8]  P. Lumbiganon,et al.  Interval debulking surgery for advanced epithelial ovarian cancer. , 2016, The Cochrane database of systematic reviews.

[9]  H. Kitchener,et al.  Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial , 2015, The Lancet.

[10]  G. Baiocchi,et al.  Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer , 2015, Annals of Surgical Oncology.

[11]  H. Hricak,et al.  A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. , 2014, Gynecologic oncology.

[12]  G. Scambia,et al.  Timing and Pattern of Recurrence in Ovarian Cancer Patients with High Tumor Dissemination Treated with Primary Debulking Surgery Versus Neoadjuvant Chemotherapy , 2013, Annals of Surgical Oncology.

[13]  R. Berkowitz,et al.  Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. , 2013, Gynecologic oncology.

[14]  Herbert Yu,et al.  Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV) , 2013, Journal of surgical oncology.

[15]  G. Kenter,et al.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.

[16]  M. Hatae,et al.  Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. , 2009, Gynecologic oncology.

[17]  J. McAlpine,et al.  Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. , 2007, Gynecologic oncology.

[18]  A. Jazaeri,et al.  Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer. , 2006, American journal of obstetrics and gynecology.

[19]  S. Rubin,et al.  Secondary surgical cytoreduction for advanced ovarian carcinoma. , 2004, The New England journal of medicine.

[20]  Hys Ngan,et al.  Carcinoma of the Ovary , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[21]  G. Tulunay,et al.  Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma , 2001, International Journal of Gynecologic Cancer.

[22]  C. Pomel,et al.  Cytoreductive surgery for advanced stages of ovarian cancer. , 2000, Seminars in surgical oncology.

[23]  M. Buyse,et al.  The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. , 1995, The New England journal of medicine.

[24]  J. Wharton,et al.  Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. , 1991, Gynecologic oncology.

[25]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.

[26]  D. Chi,et al.  Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. , 2011, Gynecologic oncology.

[27]  P. Lumbiganon,et al.  Interval debulking surgery for advanced epithelial ovarian cancer. , 2010, The Cochrane database of systematic reviews.

[28]  A. Sato,et al.  Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. , 2008, Japanese journal of clinical oncology.

[29]  D. Atallah,et al.  Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  S. Rakar,et al.  Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study. , 2002, European journal of gynaecological oncology.

[31]  P. Schwartz,et al.  Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. , 1999, Gynecologic oncology.